Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OM3 Tear vs REFRESH OPTIVE ADVANCED in dry eye disease
NCT02553772Phase 3Completed
- Sponsor
- Allergan
- Start
- Jan 2016
- Primary completion
- Sep 2016
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 3 trial of NGE-UD in dry eye syndrome (DED), sponsored by Allergan. Started Jan 2016; status: completed.
02
Drugs
NGE-UD
03
Conditions
dry eye syndrome (DED)
Beyond the preview
Go deeper on NCT02553772.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02553772.